Neovasc is a leader in the development of minimally invasive therapies for two of the most vexing challenges in cardiovascular care: refractory angina and mitral valve regurgitation. The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in treating advanced heart disease. Reducer is CE-marked for use in the EU and is FDA approved for investigational use in the US. Tiara is not commercially available and is currently being evaluated in two ongoing clinical trials. Headquartered in Vancouver, BC and Minneapolis, MN, Neovasc is publicly traded on both the NASDAQ and the Toronto Stock Exchange (NVCN).